Study drug plus chemo for cervical cancer after prior immunotherapy
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This Phase 2 trial tests cadonilimab (an immunotherapy) combined with nab-paclitaxel (chemo) to treat cervical cancer that has come back or spread and did not respond to prior immune checkpoint medicines. It may help shrink tumors and improve disease control after prior immunotherapy failure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman, age 18 to 75, and can understand and sign consent before starting.
- Your cervical cancer is confirmed by tissue testing and is recurring or metastatic (has spread).
- You previously tried immune checkpoint drugs (PD-1, PD-L1, or CTLA-4) and they did not work.
- You have at least one measurable tumor spot that can be tracked on scans (or it can be proven by biopsy).
- You can provide recent tumor tissue (either stored from within 5 years or a new biopsy).
- Your body systems are strong enough (blood counts, kidney, liver, heart function) for study treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests cadonilimab (an immunotherapy medicine) combined with anlotinib (a targeted drug) for advanced or recurrent cervical cancer that has already been treated. It may help shrink tumors or slow cancer growth, especially if the cancer has a measurable area doctors can track.
This trial tests if giving chemotherapy plus an immunotherapy drug before surgery can help shrink tumors and improve outcomes for patients with stage IB2 cervical cancer that has not been treated yet. It might be an option if you have a specific type of cervical cancer that shows a certain protein (PD-L1) on your tumor cells.
This trial tests a combination of cadonilimab (an immune-boosting drug) plus chemotherapy for locally advanced cervical cancer that hasn't been treated before. The goal is to see if this combination helps shrink tumors and improve outcomes before surgery.
This trial tests whether adding an immunotherapy drug called Cadonilimab (AK104) to standard chemoradiation can help people with locally advanced cervical cancer that has not spread to distant organs. The goal is to improve treatment outcomes for those who cannot have surgery.
This trial tests a new immunotherapy drug called cadonilimab for women with cervical cancer that has returned, spread, or is advanced. The goal is to see if it works well, how safe it is, and if it costs less than standard treatments.
This trial tests a new immunotherapy drug called cadonilimab (AK104) combined with standard chemotherapy for women whose small cell neuroendocrine cervical cancer has returned or spread. The goal is to see if this combination helps shrink tumors or slow the cancer better than chemotherapy alone.
Hear when a new Uterine Cervical Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.